Natalie Sacks
Partner Novo Holdings US
Dr. Natalie Sacks joined Venture Investments in 2022 as a Venture Partner based in the San Francisco office.
Dr. Sacks is an oncologist and drug developer with over 20 years of experience in the biotechnology industry. Prior to joining Venture Investments, she served as the Chief Medical Officer at Harpoon Therapeutics. Prior to that, she held various development and executive leadership roles at multiple companies including at Onyx Pharmaceuticals (acquired by Amgen), Aduro, Exelixis, and Cell Genesys. She has been responsible for all aspects of development ranging from initial IND to the late-stage development of commercially available oncology therapeutics.
Dr. Sacks held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her B.A. in Mathematics from Bryn Mawr College, her M.S. in Biostatistics from the Harvard University School of Public Health, and her M.D. from the University of Pennsylvania School of Medicine.
Seminars
- How has investor sentiment evolved as neuropsychiatry moves from scientific validation toward commercial execution and scalability?
- What constitutes an attractive opportunity in today's investment landscape?
- How are investors evaluating next-generation psychedelic approaches, including non-hallucinogenic neuroplastogens and differentiated product profiles?
- Which emerging therapeutic areas and indications are generating the greatest excitement across neuropsychiatry?
- What scientific, clinical and commercial milestones are investors looking for before committing capital?
